A recent study (E Sag et al. J Pediatr 2020; 224: 166-70) provided some useful information about the development of leukopenia in children receiving colchicine.
This study included 213 patients receiving colchicine at doses between 0.5 mg adn 2 mg/day. Routine labs were obtained 2 weeks after starting treatment, at 3 months, and then every 6 months. If leukopenia was identified, f/u labs were obtained 1 week later. Colchicine doses were decreased in patients with persistent leukopenia.
Key findings:
- 23 (10.8%) developed reversible leukopenia. No cases of leukopenia were severe and there was not an increased rate of infections.
Related blog posts:
gutsandgrowth 